F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comPiramal Pharma Ltd, a key player in India’s pharmaceutical and healthcare solutions ecosystem, operates across contract development and manufacturing (CDMO), complex hospital generics, and India consumer healthcare. The company has been strengthening its portfolio through capacity expansion, operational efficiency, and improved global market reach.
With institutional confidence, expanding CDMO demand, and growing specialty pharma operations, Piramal Pharma is positioned for steady long-term growth. In this article, we analyze its share price targets from 2026 to 2030, based on the real market data, sector performance, and future business potential.
| Detail | Value |
|---|---|
| Open | ₹174.65 |
| Previous Close | ₹174.65 |
| Day’s High | ₹174.66 |
| Day’s Low | ₹170.40 |
| VWAP | ₹172.35 |
| Volume | 19,21,357 |
| Value (Lacs) | 3,327.02 |
| 20D Avg Volume | 42,36,914 |
| 20D Avg Delivery (%) | 25.34% |
| 52-Week High | ₹273.35 |
| 52-Week Low | ₹170.40 |
| All-Time High | ₹307.90 |
| All-Time Low | ₹63.10 |
| Market Capitalization | ₹23,017 Cr |
| UC Limit | ₹192.11 |
| LC Limit | ₹157.19 |
| Face Value | ₹10 |
| Book Value Per Share | ₹59.53 |
| Beta | 1.01 |
| Dividend Yield | 0.08% |
| Investor Type | Holding (%) |
|---|---|
| Promoters | 34.86% |
| Foreign Institutions | 30.27% |
| Retail & Others | 19.98% |
| Mutual Funds | 13.11% |
| Other Domestic Institutions | 1.78% |
High FII participation highlights global investor confidence in Piramal Pharma’s long-term strategy.
Piramal Pharma is a diversified pharmaceutical company with global operations and a presence across high-growth healthcare verticals.
CDMO (Contract Development & Manufacturing): A fast-growing global division serving innovator pharma companies.
Complex Hospital Generics: Including injectable anesthesia and pain management solutions.
India Consumer Healthcare: Over-the-counter wellness and personal-care products.
Global-scale CDMO capabilities
Strong partnerships with multinational pharmaceutical companies
Diversified product portfolio reducing dependency on any single segment
Increasing global demand for outsourced pharmaceutical manufacturing
Strengthening regulatory compliance and quality systems
CDMO sector projected to grow steadily due to outsourcing by global innovators
Demand rising for complex generics and high-value injectables
Indian consumer health market continues expanding with urban lifestyle changes
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 185 | 210 |
| 2027 | 215 | 250 |
| 2028 | 250 | 295 |
| 2029 | 295 | 345 |
| 2030 | 345 | 410 |
These projections reflect improving operational efficiencies, expanding CDMO demand, and strengthening financial performance.
Piramal Pharma is expected to stabilize profitability through cost optimization and improved manufacturing utilization.
Growth Drivers:
Higher CDMO orders
Streamlined operations post-restructuring
Increased demand in hospital generics
Investment View: Good for investors seeking a moderate-growth pharma play.
By 2027, the company’s global outsourcing partnerships may expand significantly.
Growth Drivers:
Scaling of CDMO facilities
Better revenue mix from high-margin segments
Increased consumer healthcare penetration
Investment View: Suitable for long-term growth portfolios.
As Piramal Pharma strengthens its international presence, revenue diversification is expected to widen.
Growth Drivers:
Expansion in regulated markets
Strengthened FDA and EMA compliance records
Growing hospital generics portfolio
Investment View: Attractive for investors seeking exposure to global pharma outsourcing.
A mature CDMO pipeline and strong product launches may push the company into a higher valuation range.
Growth Drivers:
Improved EBITDA margins
Long-term CDMO contracts
Increased product approvals
Investment View: Can deliver strong compounding returns.
By 2030, Piramal Pharma could evolve into one of India’s top global CDMO and specialty pharma companies.
Growth Drivers:
Strong global client portfolio
High-value injectable generics growth
Consistent revenue from consumer healthcare
Investment View: Good long-term potential for investors seeking stability plus growth.
Strong FII and mutual fund confidence
Global CDMO growth opportunity
Improving operating performance
Diversified pharma portfolio
Favorable long-term industry outlook
Regulatory compliance challenges
Currency fluctuations affecting global revenues
Competitive pressure in generics market
Short-term profitability fluctuations
Piramal Pharma Ltd is strategically positioned across CDMO, generics, and consumer healthcare—three high-growth areas within global pharmaceuticals. With strong institutional ownership, an improving cost structure, and expanding international partnerships, the company is well-set for long-term growth.
Based on current fundamentals and industry direction, Piramal Pharma’s stock may reach ₹345 to ₹410 by 2030, reflecting steady progress and expanding global opportunities.
1. What is the current share price of Piramal Pharma Ltd?
As per your data, it opened at ₹174.65.
2. What is the 2026 target?
₹185 to ₹210.
3. Is Piramal Pharma good for the long term?
Yes, due to CDMO expansion and consistent global demand.
4. What is the 2030 price target?
₹345 to ₹410.
5. What affects Piramal Pharma’s share price the most?
Global CDMO orders, regulatory approvals, operational efficiency, and market demand for complex generics.
Disclaimer: This article is for informational purposes only. Please consult a financial advisor before investing.
Register & Login